Vivoryon Therapeutics N.V. Announces Upcoming Conference
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) is gearing up to unveil its financial results for the third quarter ending September 30, 2025. The company specializes in developing innovative small molecule therapies, primarily targeting inflammatory and fibrotic kidney disorders. This event will be held on December 4, 2025, and will be accompanied by a comprehensive corporate update, making it a key date for stakeholders and patients alike.
Details About the Conference Call
Event Timing and Access
The conference call is scheduled to commence at 3:00 PM CET / 9:00 AM EST. It will be accessible to the public through a live audio webcast and a dedicated phone line. Participants are encouraged to log in or call 15 minutes prior to prevent delays.
How to Participate
To facilitate easier access, attendees can pre-register through Vivoryon’s official conference registration page. Upon registration, participants will receive unique dial-in details to join the call smoothly.
Company’s Commitment to Innovation
Vivoryon Therapeutics is at the forefront of biotechnology with a commitment to advancing treatments aimed at severe inflammatory and fibrotic diseases. The firm is particularly focused on transforming the course of kidney diseases by targeting functionally important proteins implicated in these conditions. Their flagship drug candidate, varoglutamstat, has shown promising potential as a treatment for diabetic kidney disease.
Understanding the Market and Company Goals
The market for treatments addressing kidney-related ailments is vast and expanding. With increasing rates of diabetes and related conditions impacting kidney function, Vivoryon’s innovative approaches could yield significant results. The company's ongoing clinical trials are vital to determining the efficacy of its therapies and shaping future treatment paradigms.
Commitment to Patient Outcomes
Vivoryon Therapeutics emphasizes its mission to enhance patient outcomes through scientific innovation. Their research and development efforts are deeply rooted in a patient-centered approach, aiming to provide effective, practical solutions for those suffering from chronic kidney disorders.
Contact Information for Further Inquiries
For detailed inquiries and investor relations, individuals can reach out to the company's Director of Investor Relations, Dr. Manuela Bader, via email. LifeSci Advisors, representing Vivoryon, is another point of contact for investor communications.
Media Relations Support
For media-related queries, Trophic Communications is available to provide proper assistance and connections to company representatives. They are well-equipped to handle inquiries, ensuring that accurate information is disseminated to the public.
Frequently Asked Questions
What date will Vivoryon report its Q3 2025 results?
Vivoryon will report its Q3 2025 financial results on December 4, 2025.
How can I join the conference call?
Participants can pre-register through Vivoryon’s website to receive access details for the conference call.
What is Vivoryon’s primary focus?
Vivoryon Therapeutics focuses on developing treatments for inflammatory and fibrotic disorders, with a particular emphasis on kidney diseases.
What is the significance of varoglutamstat?
Varoglutamstat is Vivoryon’s leading drug candidate, aimed at treating diabetic kidney disease, representing a pivotal step in their research.
Who can I contact for investor relations?
Dr. Manuela Bader is the Director of Investor Relations at Vivoryon and can be contacted via email for any inquiries.